Electronic Supplementary Material (ESI) for Organic Chemistry Frontiers. This journal is © the Partner Organisations 2020

Supporting Information

Elodeoidins A-H, acylphloroglucinol meroterpenoids possessing diverse rearranged

skeletons from Hypericum elodeoides

Qi-Ji Li, Peng-Fei Tang, Xin Zhou, Wei-Jia Lu, Wen-Jun Xu, Jun Luo*, Ling-Yi Kong*

Affiliations

Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural

Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009,

People's Republic of China.

Corresponding authors

* Ling-Yi Kong:

E-mail: cpu_lykong@126.com

Tel/Fax: +86-25-8327-1405

* Jun Luo:

E-mail: luojun@cpu.edu.cn

Tel/Fax: +86-25-8327-1405

CONTENTS

Table S1 (COOMILE) and 13C (15OMILE) NMD Date for 1 4	
Table S1. H (OUDMHZ) and C (TSUMHZ) NMIK Data for 1-4.	4
Table S2. ¹ H (600MHz) and ¹³ C (150MHz) NMR Data for 5-8	5
Mosher's method	6
Figure S1 Key Values of $\Delta \delta_{\rm H} (S - R)$ for the MTPA Esters of (+)-1	6
ECD and ¹³ C NMR calculated spectra	6
Figure S2 Experimental and computational ECD spectra of 1-6	6
Figure S3 The experimental and calculated ¹³ C NMR linear correlation	7
2D NMR correlations and HPLC chiral analysis chromatogram analysis	7
Figure S4 Kev ¹ H- ¹ H COSY, HMBC and ROESY correlations of 7.	7
Figure S5 Key ROESY correlations of 8.	7
Figure S6 HPLC chiral analysis chromatogram for 1-8	7
EXPERIMENTAL SECTION	8
Experimental Procedures	8
Plant material	8
Extraction and isolation	8
Physical and chemical data	9
Anti-inflammatory activity	10
CALCULATION SECTION	10
Calculation quantum-chemical ¹³ C NMR for 5	10
Calculation FCD for 1-6	12
NMR HRESIMS LIV and IR spectrum of 1 (Figure \$7-\$15)	14
Figure S7 ¹ H NMR (600 MHz) spectrum of 1 in CDCl ₂ and DMSO ₂ d_c	14
Figure S8 ¹³ C NMR (150 MHz) spectrum of 1 in CDCl ₂ and DMSO <i>d</i> ₆ .	15
Figure S9 HSOC spectrum of 1 in CDCl ₂ and DMSO- d_c	16
Figure S10 HMRC spectrum of 1 in CDCl ₂ and DMSO- a_0 .	17
Figure S11 ROFSV spectrum of 1 in CDCl ₂ and DMSO- d_c	18
Figure S12 $^{1}H_{-}^{1}H_{-$	10
Figure \$12 HRESIMS spectrum of 1	10
Figure \$14 IR spectrum of 1	20
Figure \$15 UV spectrum of 1	20
NMR HRESIMS LIV and IR spectrum of 2 (Figure \$16-\$23)	.20
TWIK, TIKESIWS, OV, and IK Spectrum Of 2 (Tigue 570-523)	. 41
$\mu_1 \alpha_1 \mu_2 \propto 1.6 \pm \mu_1 \times 1.0 / \mu_2 / 6 / (1 \times 1.0 +$	21
Figure S16 ¹ H NMR (600 MHz) spectrum of 2 in CDCl ₃	.21
Figure S16 ¹ H NMR (600 MHz) spectrum of 2 in CDCl ₃ Figure S17 ¹³ C NMR (150 MHz) spectrum of 2 in CDCl ₃	.21
Figure S16 ¹ H NMR (600 MHz) spectrum of 2 in CDCl ₃ . Figure S17 ¹³ C NMR (150 MHz) spectrum of 2 in CDCl ₃ . Figure S18 HSQC spectrum of 2 in CDCl ₃ .	.21 .21 .22
Figure S16 ¹ H NMR (600 MHz) spectrum of 2 in CDCl ₃ . Figure S17 ¹³ C NMR (150 MHz) spectrum of 2 in CDCl ₃ . Figure S18 HSQC spectrum of 2 in CDCl ₃ . Figure S19 HMBC spectrum of 2 in CDCl ₃ .	.21 .21 .22 .22
Figure S16 ¹ H NMR (600 MHz) spectrum of 2 in CDCl ₃ . Figure S17 ¹³ C NMR (150 MHz) spectrum of 2 in CDCl ₃ . Figure S18 HSQC spectrum of 2 in CDCl ₃ . Figure S19 HMBC spectrum of 2 in CDCl ₃ . Figure S20 ROESY spectrum of 2 in CDCl ₃ .	.21 .21 .22 .22 .23
Figure S16 ¹ H NMR (600 MHz) spectrum of 2 in CDCl ₃ . Figure S17 ¹³ C NMR (150 MHz) spectrum of 2 in CDCl ₃ . Figure S18 HSQC spectrum of 2 in CDCl ₃ . Figure S19 HMBC spectrum of 2 in CDCl ₃ . Figure S20 ROESY spectrum of 2 in CDCl ₃ . Figure S21 HRESIMS spectrum of 2 .	.21 .21 .22 .22 .23 .23
Figure S16 ¹ H NMR (600 MHz) spectrum of 2 in CDCl ₃ . Figure S17 ¹³ C NMR (150 MHz) spectrum of 2 in CDCl ₃ . Figure S18 HSQC spectrum of 2 in CDCl ₃ . Figure S19 HMBC spectrum of 2 in CDCl ₃ . Figure S20 ROESY spectrum of 2 in CDCl ₃ . Figure S21 HRESIMS spectrum of 2. Figure S22 IN spectrum of 2.	.21 .21 .22 .22 .23 .23 .23 .24
Figure S16 ¹ H NMR (600 MHz) spectrum of 2 in CDCl ₃ . Figure S17 ¹³ C NMR (150 MHz) spectrum of 2 in CDCl ₃ . Figure S18 HSQC spectrum of 2 in CDCl ₃ . Figure S19 HMBC spectrum of 2 in CDCl ₃ . Figure S20 ROESY spectrum of 2 in CDCl ₃ . Figure S21 HRESIMS spectrum of 2. Figure S22 IR spectrum of 2. Figure S23 UV spectrum of 2.	.21 .21 .22 .22 .23 .23 .24 .24
Figure S16 ¹ H NMR (600 MHz) spectrum of 2 in CDCl ₃ . Figure S17 ¹³ C NMR (150 MHz) spectrum of 2 in CDCl ₃ . Figure S18 HSQC spectrum of 2 in CDCl ₃ . Figure S19 HMBC spectrum of 2 in CDCl ₃ . Figure S20 ROESY spectrum of 2 in CDCl ₃ . Figure S21 HRESIMS spectrum of 2. Figure S22 IR spectrum of 2. Figure S23 UV spectrum of 2. Figure S23 UV spectrum of 2. Figure S23 UV spectrum of 3 (Figure S24-S32). NMR, HRESIMS, UV, and IR spectrum of 3 (Figure S24-S32).	.21 .22 .22 .23 .23 .23 .24 .24 .25
 Figure S16 ¹H NMR (600 MHz) spectrum of 2 in CDCl₃. Figure S17 ¹³C NMR (150 MHz) spectrum of 2 in CDCl₃. Figure S18 HSQC spectrum of 2 in CDCl₃. Figure S19 HMBC spectrum of 2 in CDCl₃. Figure S20 ROESY spectrum of 2 in CDCl₃. Figure S21 HRESIMS spectrum of 2. Figure S22 IR spectrum of 2. Figure S23 UV spectrum of 2. Figure S23 UV spectrum of 2. NMR, HRESIMS, UV, and IR spectrum of 3 (Figure S24-S32). Figure S24 ¹H NMR (600 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S25 ¹³C NMR (150 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. 	.21 .22 .22 .23 .23 .23 .24 .24 .25 .25
 Figure S16 ¹H NMR (600 MHz) spectrum of 2 in CDCl₃. Figure S17 ¹³C NMR (150 MHz) spectrum of 2 in CDCl₃. Figure S18 HSQC spectrum of 2 in CDCl₃. Figure S19 HMBC spectrum of 2 in CDCl₃. Figure S20 ROESY spectrum of 2 in CDCl₃. Figure S21 HRESIMS spectrum of 2 in CDCl₃. Figure S21 HRESIMS spectrum of 2. Figure S22 IR spectrum of 2. Figure S23 UV spectrum of 2. Figure S23 UV spectrum of 2. Figure S24 ¹H NMR (600 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S25 ¹³C NMR (150 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. 	.21 .22 .22 .23 .23 .23 .23 .24 .24 .25 .25 .26
 Figure S16 'H NMR (600 MHz) spectrum of 2 in CDCl₃. Figure S17 ¹³C NMR (150 MHz) spectrum of 2 in CDCl₃. Figure S18 HSQC spectrum of 2 in CDCl₃. Figure S19 HMBC spectrum of 2 in CDCl₃. Figure S20 ROESY spectrum of 2 in CDCl₃. Figure S21 HRESIMS spectrum of 2 in CDCl₃. Figure S21 HRESIMS spectrum of 2. Figure S22 IR spectrum of 2. Figure S23 UV spectrum of 2. Figure S23 UV spectrum of 2. Figure S24 ¹H NMR (600 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S25 ¹³C NMR (150 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S26 HSQC spectrum of 3 in CDCl₃ and DMSO-d₆. 	.21 .22 .22 .23 .23 .24 .24 .25 .25 .26 .27
 Figure S16 'H NMR (600 MHz) spectrum of 2 in CDCl₃. Figure S17 ¹³C NMR (150 MHz) spectrum of 2 in CDCl₃. Figure S18 HSQC spectrum of 2 in CDCl₃. Figure S19 HMBC spectrum of 2 in CDCl₃. Figure S20 ROESY spectrum of 2 in CDCl₃. Figure S21 HRESIMS spectrum of 2. Figure S22 IR spectrum of 2. Figure S23 UV spectrum of 2. Figure S23 UV spectrum of 2. Figure S23 UV spectrum of 2. Figure S24 ¹H NMR (600 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S25 ¹³C NMR (150 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S26 HSQC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S27 HMBC spectrum of 3 in CDCl₃ and DMSO-d₆. 	.21 .22 .22 .23 .23 .24 .24 .25 .26 .27 .28
 Figure S16 ¹H NMR (600 MHz) spectrum of 2 in CDCl₃. Figure S17 ¹³C NMR (150 MHz) spectrum of 2 in CDCl₃. Figure S18 HSQC spectrum of 2 in CDCl₃. Figure S19 HMBC spectrum of 2 in CDCl₃. Figure S20 ROESY spectrum of 2 in CDCl₃. Figure S21 HRESIMS spectrum of 2. Figure S22 IR spectrum of 2. Figure S23 UV spectrum of 2. Figure S23 UV spectrum of 2. Figure S24 ¹H NMR (600 MHz) spectrum of 3 (Figure S24-S32). Figure S24 ¹H NMR (600 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S25 ¹³C NMR (150 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S26 HSQC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S27 HMBC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S28 ROESY spectrum of 3 in CDCl₃ and DMSO-d₆. 	.21 .22 .22 .22 .23 .24 .24 .25 .26 .27 .28 .29
 Figure S16 'H NMR (600 MHz) spectrum of 2 in CDCl₃. Figure S17 ¹³C NMR (150 MHz) spectrum of 2 in CDCl₃. Figure S18 HSQC spectrum of 2 in CDCl₃. Figure S19 HMBC spectrum of 2 in CDCl₃. Figure S20 ROESY spectrum of 2 in CDCl₃. Figure S21 HRESIMS spectrum of 2. Figure S22 IR spectrum of 2. Figure S23 UV spectrum of 2. Figure S23 UV spectrum of 2. Figure S24 ¹H NMR (600 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S25 ¹³C NMR (150 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S26 HSQC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S27 HMBC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S28 ROESY spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S28 ROESY spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S28 ROESY spectrum of 3 in CDCl₃ and DMSO-d₆. 	.21 .22 .22 .23 .24 .24 .25 .25 .26 .27 .28 .29 .30
 Figure S16 [']H NMR (600 MHz) spectrum of 2 in CDCl₃. Figure S17 ¹³C NMR (150 MHz) spectrum of 2 in CDCl₃. Figure S18 HSQC spectrum of 2 in CDCl₃. Figure S19 HMBC spectrum of 2 in CDCl₃. Figure S20 ROESY spectrum of 2 in CDCl₃. Figure S21 HRESIMS spectrum of 2 in CDCl₃. Figure S21 HRESIMS spectrum of 2. Figure S23 UV spectrum of 2. Figure S23 UV spectrum of 2. Figure S24 ¹H NMR (600 MHz) spectrum of 3 (Figure S24-S32). Figure S24 ¹H NMR (600 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S25 ¹³C NMR (150 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S26 HSQC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S27 HMBC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S28 ROESY spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S29 ¹H-¹H COSY spectrum of 3 in CDCl₃. Figure S30 HRESIMS spectrum of 3. Figure S21 HRESIMS spectrum of 3. 	.21 .22 .22 .23 .24 .24 .25 .25 .26 .27 .28 .29 .30 .30
 Figure S16 ¹H NMR (600 MHz) spectrum of 2 in CDCl₃. Figure S17 ¹³C NMR (150 MHz) spectrum of 2 in CDCl₃. Figure S18 HSQC spectrum of 2 in CDCl₃. Figure S19 HMBC spectrum of 2 in CDCl₃. Figure S20 ROESY spectrum of 2 in CDCl₃. Figure S21 HRESIMS spectrum of 2. Figure S22 IR spectrum of 2. Figure S23 UV spectrum of 2. Figure S24 ¹H NMR (600 MHz) spectrum of 3 (Figure S24-S32). Figure S24 ¹H NMR (600 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S25 ¹³C NMR (150 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S26 HSQC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S27 HMBC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S28 ROESY spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S29 ¹H-¹H COSY spectrum of 3 in CDCl₃. Figure S30 HRESIMS spectrum of 3. Figure S31 IR spectrum of 3. Figure S21 IR spectrum of 3. Figure S22 IV spectrum of 3. Figure S23 IIR spectrum of 3. Figure S24 IIR spectrum of 3. 	.21 .21 .22 .23 .23 .23 .24 .25 .25 .26 .27 .28 .29 .30 .30 .31
 Figure S16 'H NMR (600 MHz) spectrum of 2 in CDCl₃. Figure S17 ¹³C NMR (150 MHz) spectrum of 2 in CDCl₃. Figure S18 HSQC spectrum of 2 in CDCl₃. Figure S19 HMBC spectrum of 2 in CDCl₃. Figure S20 ROESY spectrum of 2 in CDCl₃. Figure S21 HRESIMS spectrum of 2. Figure S22 IR spectrum of 2. Figure S23 UV spectrum of 2. Figure S23 UV spectrum of 2. Figure S23 UV spectrum of 2. Figure S24 ¹H NMR (600 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S25 ¹³C NMR (150 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S26 HSQC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S27 HMBC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S28 ROESY spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S29 ¹H-¹H COSY spectrum of 3 in CDCl₃. Figure S30 HRESIMS spectrum of 3. Figure S31 IR spectrum of 3. Figure S32 UV spectrum of 3. 	.21 .21 .22 .22 .23 .23 .23 .24 .24 .25 .25 .26 .27 .28 .29 .30 .30 .31 .31
 Figure S16 'H NMR (600 MHz) spectrum of 2 in CDCl₃. Figure S17 ¹³C NMR (150 MHz) spectrum of 2 in CDCl₃. Figure S18 HSQC spectrum of 2 in CDCl₃. Figure S19 HMBC spectrum of 2 in CDCl₃. Figure S20 ROESY spectrum of 2 in CDCl₃. Figure S21 HRESIMS spectrum of 2. Figure S22 IR spectrum of 2. Figure S23 UV spectrum of 2. Figure S23 UV spectrum of 2. Figure S24 ¹H NMR (600 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S25 ¹³C NMR (150 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S26 HSQC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S27 HMBC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S28 ROESY spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S29 ¹H-¹H COSY spectrum of 3 in CDCl₃. Figure S31 IR spectrum of 3. Figure S31 IR spectrum of 3. Figure S32 UV spectrum of 3. Figure S32 UV spectrum of 3. Figure S32 UV spectrum of 3. Figure S31 IR spectrum of 3. Figure S32 UV spectrum of 3. 	.21 .22 .22 .23 .23 .24 .24 .25 .26 .27 .28 .29 .30 .31 .31 .32
 Figure S16 ¹H NMR (600 MHz) spectrum of 2 in CDCl₃. Figure S17 ¹³C NMR (150 MHz) spectrum of 2 in CDCl₃. Figure S18 HSQC spectrum of 2 in CDCl₃. Figure S19 HMBC spectrum of 2 in CDCl₃. Figure S20 ROESY spectrum of 2 in CDCl₃. Figure S21 HRESIMS spectrum of 2. Figure S22 IR spectrum of 2. Figure S23 UV spectrum of 2. Figure S23 UV spectrum of 2. Figure S24 ¹H NMR (600 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S25 ¹³C NMR (150 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S26 HSQC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S27 HMBC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S28 ROESY spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S29 ¹H-¹H COSY spectrum of 3 in CDCl₃. Figure S30 HRESIMS spectrum of 3. Figure S31 IR spectrum of 3. Figure S32 IV spectrum of 3. Figure S32 IV spectrum of 3. Figure S32 IV spectrum of 3. Figure S31 IR spectrum of 3. Figure S32 IV spectrum of 3. Figure S33 ¹H NMR (600 MHz) spectrum of 4 in MeOD. Figure S33 ¹H NMR (600 MHz) spectrum of 4 in MeOD. 	.21 .21 .22 .23 .23 .24 .24 .25 .25 .26 .27 .28 .29 .30 .31 .31 .32 .32
 Figure S16 'H NMR (600 MHz) spectrum of 2 in CDCl₃ Figure S17 ¹³C NMR (150 MHz) spectrum of 2 in CDCl₃ Figure S18 HSQC spectrum of 2 in CDCl₃ Figure S19 HMBC spectrum of 2 in CDCl₃ Figure S20 ROESY spectrum of 2 in CDCl₃ Figure S21 HRESIMS spectrum of 2. Figure S21 HRESIMS spectrum of 2. Figure S23 UV spectrum of 2. Figure S23 UV spectrum of 2. Figure S24 ¹H NMR (600 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S25 ¹³C NMR (150 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S26 HSQC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S27 HMBC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S28 ROESY spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S29 ¹H-¹H COSY spectrum of 3 in CDCl₃. Figure S30 HRESIMS spectrum of 3. Figure S31 IR spectrum of 3. Figure S31 IR spectrum of 3. Figure S31 IR spectrum of 3. Figure S32 UV spectrum of 3. Figure S31 IR spectrum of 3. Figure S31 ¹H NMR (600 MHz) spectrum of 4 (Figure S33-S40). Figure S33 ¹H NMR (600 MHz) spectrum of 4 in MeOD. Figure S34 ¹³C NMR (150 MHz) spectrum of 4 in MeOD. 	.21 .21 .22 .23 .23 .24 .24 .25 .26 .27 .28 .29 .30 .31 .31 .32 .32 .32
 Figure S16 'H NMR (600 MHz) spectrum of 2 in CDCl₃. Figure S17 ¹³C NMR (150 MHz) spectrum of 2 in CDCl₃. Figure S18 HSQC spectrum of 2 in CDCl₃. Figure S19 HMBC spectrum of 2 in CDCl₃. Figure S20 ROESY spectrum of 2 in CDCl₃. Figure S21 HRESIMS spectrum of 2. Figure S21 IR spectrum of 2. Figure S23 UV spectrum of 2. Figure S24 ¹H NMR (600 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S25 ¹³C NMR (150 MHz) spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S26 HSQC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S27 HMBC spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S28 ROESY spectrum of 3 in CDCl₃ and DMSO-d₆. Figure S29 ¹H-¹H COSY spectrum of 3 in CDCl₃. Figure S30 HRESIMS spectrum of 3. Figure S31 IR spectrum of 4. Figure S33 ¹H NMR (600 MHz) spectrum of 4 in MeOD. Figure S34 ¹³C NMR (150 MHz) spectrum of 4 in MeOD. Figure S35 HSQC spectrum of 4 in MeOD. 	.21 .22 .22 .23 .23 .24 .24 .25 .26 .27 .28 .29 .30 .31 .31 .32 .32 .32 .32

Figure S37 ROESY spectrum of 4 in MeOD.	34
Figure S38 HRESIMS spectrum of 4	34
Figure S39 IR spectrum of 4.	35
Figure S40 UV spectrum of 4	35
NMR, HRESIMS, UV, and IR spectrum of 5 (Figure S41-S49)	
Figure S41 ¹ H NMR (600 MHz) spectrum of 5 in CDCl ₃ and DMSO- d_6	
Figure S42 ¹³ C NMR (150 MHz) spectrum of 5 in CDCl ₃ and DMSO- d_6	
Figure S43 HSOC spectrum of 5 in CDCl ₃ and DMSO- d_6	38
Figure S44 HMBC spectrum of 5 in CDCl ₃ and DMSO- <i>d</i> ₆	
Figure S45 ROESY spectrum of 5 in CDCl ₃ and DMSO-d ₆	40
Figure S46 ¹ H- ¹ H COSY spectrum of 5 in CDCl ₃	41
Figure S47 HRESIMS spectrum of 5	41
Figure S48 IR spectrum of 5	42
Figure S49 UV spectrum of 5	42
NMR HRESINS UV and IR spectrum of 6 (Figure S50-S57)	43
Figure S50 ¹ H NMR (600 MHz) spectrum of 6 in CDCl ₂	43
Figure S51 ¹³ C NMR (150 MHz) spectrum of 6 in CDCl ₂	43
Figure S52 HSOC spectrum of 6 in CDCl ₂	J 44
Figure \$52 HMBC spectrum of 6 in CDCl ₂	++
Figure S53 HADE spectrum of 6 in CDCl ₂	++
Figure S54 ROEST spectrum of 6	45
Figure \$55 IRESING Spectrum of 6	45
Figure \$50 IK spectrum of 6	40
NMD HDESIMS IV and ID spectrum of 7 (Figure \$58,866)	40
Figure S58 14 NMD (600 MHz) spectrum of 7 in CDC1.	47
Figure S50 ⁻¹³ C NMR (150 MHz) spectrum of 7 in CDC1.	47
Figure S60 HSOC spectrum of 7 in CDCl.	47 70
Figure S61 HMPC spectrum of 7 in CDC1.	40
Figure S62 III III COSV spectrum of 7 in CDC1	40
Figure S62 POESV apactrum of 7 in CDCl	49
Figure S64 LIDESING spectrum of 7	49
Figure S65 ID spectrum of 7	
Figure Sos IK spectrum of 7.	
Figure 500 UV spectrum of 9 (Figure 567 575)	
NMR, HRESIMS, UV, and IK spectrum of δ (Figure 50/-5/5)	52
Figure S67 ¹ H NMR (600 MHz) spectrum of δ in CDCl ₃	52
Figure S68 ¹³ C NMR (150 MHZ) spectrum of δ in CDCl ₃ .	
Figure S69 HSQC spectrum of 8 in CDCl ₃	
Figure 570 HMBC spectrum of 8 in CDCI ₃	
Figure S/1 'H-'H COSY spectrum of 8 in CDCl ₃ .	
Figure S72 KOESY spectrum of 8 in CDCl ₃ .	
Figure 5/5 HRESINIS spectrum of 8.	
Figure S/4 IK spectrum of 8.	
Figure 5/5 UV spectrum of $\mathbf{\delta}$.	
NMR and HRESIMS spectrum of 9 (Figure 5/6-5/8)	
Figure S/6 ¹ H NMK (600 MHZ) spectrum of 9 in CDCl ₃	
Figure S// 13 C NMR (150 MHz) spectrum of 9 in CDCl ₃	57
Figure S/8 HRESIMS spectrum of 9.	
⁺ H NMR spectrum of MTPA Esters of $(+)$ -1 (Figure S/9-S80)	
Figure S /9 ^t H NMR (600 MHz) spectrum of <i>R</i> -MTPA Esters of (+)-1 in CDCl ₃	
Figure S80 'H NMR (600 MHz) spectrum of S-MTPA Esters of (+)-1 in CDCl ₃ .	59

NMR data of 1-8

Table S1. ¹H (600MHz) and ¹³C (150MHz) NMR Data for 1-4 (δ in ppm, J in Hz).

			1		2				3		4	
No.	$\delta_{ extsf{H}^a}$	$\delta_{c^{a}}$	$\delta_{ extsf{H}^{b}}$	δc^b	$\delta_{ extsf{H}^{b}}$	δc^b	<i>б</i> н ^{<i>a</i>}	δc^a	$\delta_{ extsf{H}^b}$	δc ^b	δ _H ^c	δ_{c^c}
1		153.1		154.2		154.2		151.4		151.3		152.0
2		150.9		153.4		153.3		150.2		149.0		149.7
3		101.9		103.8		103.8		100.6		101.7		101.0
4		203.1		203.6		203.8		203.0		203.3		203.7
5		47.2		48.1		48.0		46.9		48.2		47.2
6		203.6		203.2		203.2		203.7		205.6		203.8
7		203.9		206.3		205.9		94.6		96.4		95.7
8	3.02, sept (7.0)	41.0	2.95, sept (7.0)	41.9	2.76, m	48.4	2.47, sept (6.8)	34.1	2.68, sept (6.8)	34.9	2.40, m	41.4
9	1.09, d (7.0)	16.6	1.20, d (7.0)	17.4	1.16, d (7.0)	13.6	0.65, d (6.8)	17.6	1.13, d (6.8)	14.1	1.13, d (6.8)	9.7
10	1.06, d (7.0)	16.9	1.18, d (7.0)	16.9	1.83, m; 1.45, m	24.3	1.02, d (6.8)	14.3	0.80, d (6.8)	18.0	1.08, m	25.3
11	1.12, s	20.4	1.24, s	20.9	0.99, t (7.4)	11.7	1.04, s	19.9	1.21, s	19.0	0.87, t (7.4)	11.1
12	1.11, s	19.1	1.20, s	19.5	1.23, s	20.9	1.06, s	19.3	1.20, s	20.7	1.16, s	18.0
13					1.20, s	19.5					1.15, s	19.2
1'	2.61, dd (13.2, 4.0); 2.20, dd (13.2, 6.0)	44.3	2.89, dd (14.6, 6.0); 2.20, dd (14.6, 4.0)	48.2	2.90, dd (14.6, 6.0); 2.19, dd (14.6, 4.0	48.1	3.96, d (6.2)	75.2	4.20, d (6.2)	75.4	4.13, d (6.2)	75.5
2'	4.13, dd (6.0 4.0)	74.6	4.15, dd (6.0 4.0)	77.0	4.16, dd, (6.0, 4.0)	77.0	2.73, t (6.2)	50.8	2.78, t (6.2)	51.9	2.81, t (6.2)	51.6
3'		86.9		89.8		89.8		95.3		97.0		96.2
4'	1.50, m; 1.45, m	40.9	1.63, m; 1.56, m	40.0	1.63, m; 1.56, m	40.0	1.63, m	40.5	1.81, m	40.6	1.79, m; 1.66, m	40.2
5'	1.97, m	22.5	2.02, q (7.8)	23.3	2.02, q (7.8)	23.3	1.71, dd (7.5, 4.8); 1.64, m	28.2	1.91, m; 1.58, m	29.5	1.87, m; 1.34, m	28.4
6'	5.09, q (6.8)	124.3	5.07, t (7.1)	123.9	5.07 t, (7.1)	123.9	2.47, td (6.4, 3.2)	45.7	2.65, m	46.2	2.69, dt (10.9, 7.0)	45.9
7'		130.8		132.1		132.1		69.2		71.9		70.6
8'	1.64, s	25.5	1.67, s	25.8	1.67, s	25.8	1.07, s	28.7	1.22, s	26.9	1.21, s	27.3
9'	1.56, s	17.4	1.60, s	17.8	1.60, s	17.8	1.07, s	28.4	1.23, s	29.2	1.23, s	26.4
10'	0.96, s	19.3	1.17, s	18.2	1.17, s	18.3	1.39, s	28.6	1.53, s	29.1	1.52, s	27.8
	3.16, s, 3-OMe	49.9	3.16, s, 3-OMe	51.2	3.14, s, 3-OMe	51.2	6.82, s, 7-OH; 6.15, s , 1'-OH					

^{a 1}H and ¹³C NMR data were recorded in DMSO-*d*₆; ^b recorded in CDCl₃; ^c recorded in MeOD.

		5			6		7		8	
NO.	$\delta_{ extsf{H}}{}^{a}$	δ_{C^a}	$\delta_{ extsf{H}^{b}}$	δ_{C^b}	$\delta_{ extsf{H}^{b}}$	δ_{C^b}	$\delta_{H}{}^{b}$	δ_{C^b}	$\delta_{H^{b}}$	δc ^b
1		143.3		145.3		145.3		162.5		162.7
2		142.1		142.8		142.8		143.6		143.8
3		146.8		148.4		148.4		159.4		158.9
4		203.9		204.7		204.8		206.5		206.6
5		47.3		48.0		47.9		47.0		46.7
6		203.3		203.6		203.7		201.8		201.6
7		204.4		205.1		204.9				
8	2.86, sept (7.0)	41.2	2.89, sept (7.0)	41.9	2.70, m	48.5	4.38, q (7.2)	61.9	4.40, q (7.2)	62.0
9	1.07, d (7.0)	16.9	1.17, d (7.0)	17.3	1.14, d (7.0)	13.8	1.40, t (7.2)	14.4	1.40, t (7.2)	14.2
10	1.09, d (7.0)	16.9	1.16, d (7.0)	17.3	1.36, m; 1.24, m	24.3				
11	1.12, s	19.9	1.21, s	19.9	0.95, t (7.4)	11.7	1.18, s	19.8	1.20, s	19.9
12	1.12, s	20.3	1.20, s	20.6	1.20, s	20.2	1.18, s	20.2	1.21, s	20.0
13					1.20, s	20.6				
1'	6.58, d (2.5)	115.7	6.55, d, (2.6)	112.6	6.55, d (2.6)	112.7	2.78, dd (12.1, 10.8); 2.68, dd (12.1, 3.7)	25.9	2.97, dd (12.0, 10.7); 2.73, dd (12.0, 3.4)	28.0
2'	1.89, dd (12.7, 2.5)	47.3	1.95, dd (7.0, 2.6)	48.2	1.95, m	48.2	3.81, dd (10.8, 3.7)	75.8	4.00, dd (10.7, 3.4)	78.0
3'		75.9		77.8		77.7		82.0		71.5
4'	1.83, dd (11.0, 3.1); 1.75, ddd (13.6, 8.9, 6.7)	40.7	1.92, m; 1.77, m	40.6	1.93, m	40.6	2.08, ddd (12.0, 9.7, 5.0); 1.39, td (7.1, 3.2)	28.9	1.85, m; 1.76, m	25.8
5'	1.62, m; 1.20, m	22.8	1.78, m; 1.24, m	23.4	1.80, m	23.4	2.00, ddd (13.5, 9.7, 4.0); 1.86, m	26.1	1.93, m	21.5
6'	2.07, td (12.4, 7.0)	46.5	2.21, td (12.4, 7.0)	47.1	2.20, td (12.4, 7.0)	47.1	3.74, d (7.0)	81.7	3.33, t (2.7)	71.4
7'		80.7		81.3		81.3		74.8		75.8
8'	1.06, s	19.9	1.12, s	20.2	1.12, s	19.9	1.17, s	22.1	1.17, s	26.9
9'	1.22, s	27.9	1.31, s	28.2	1.30, s	28.1	0.91, s	25.4	1.22, s	27.7
10'	1.33, s	26.7	1.48, s	27.2	1.47, s	27.2	1.29, s	21.2	1.11, s	23.3
	4.42, s, 3'-OH									

Table S2. ¹H (600MHz) and ¹³C (150MHz) NMR Data for 5-8 (δ in ppm, J in Hz).

^a ¹H and ¹³C NMR data were recorded in DMSO-*d*₆; ^b recorded in CDCl₃.

Mosher's method

Preparation of Mosher Esters: (+)-elodeoidin A [(+)-1] (1.0 mg dissolved in 0.8 mL of CH₂Cl₂) were sequentially added pyridine (0.2 mL), 4-(dimethyl-amino) pyridine (0.1 mg), and 10 mg of (*R*)-(–)-α-methoxy-α-(trifluoromethyl)-phenylacetyl chloride. The mixture was stirred at rt overnight and passed through a glass pipette (0.5×5 cm) containing silica gel (200-300 mesh) and eluted with 3.0 mL of CH₂Cl₂. The CH₂Cl₂ residue, dried in vacuo, was redissolved in MeOH and was separated with Pre-HPLC (MeOH-H₂O, 80:20, v/v) to obtain the (*S*)-Mosher esters. Using (*S*)-(+)-α-methoxy-α-(trifluoromethyl)phenyl-acetyl chloride gave the (*R*)-Mosher esters by the foregoing method. Finally, the 2'S-configuration of (+)-1 was confirmed by Mosher model and the ¹H NMR spectra difference value (Δδ_H (*S*–*R*)) between (*S*)-and (*R*)-MTPA esters.



Figure S1 Key Values of $\Delta \delta_{\rm H}$ (S – R) for the MTPA Esters of (+)-1



ECD and ¹³C NMR calculated spectra

Figure S2 Experimental and computational ECD spectra of 1-6.



Figure S3 The experimental and calculated ¹³C NMR linear correlation

2D NMR correlations and HPLC chiral analysis chromatogram analysis



Figure S4 Key ¹H-¹H COSY, HMBC and ROESY correlations of 7.



Figure S5 Key ROESY correlations of 8.



Figure S6 HPLC chiral analysis chromatogram for 1-8.

EXPERIMENTAL SECTION

Experimental Procedures

Optical rotations were measured on a JASCOP-1020 polarimeter in MeOH at room temperature. UV spectra were scanned on a UV-2450 UV/Vis spectrophotometer (Shimadzu, Tokyo, Japan). A JASCO J-810 spectropolarimeter (Jasco, Tokyo, Japan) was used to collect electronic circular dichroism (ECD) spectra. IR spectra (KBr disks, in cm⁻¹) were acquired using a Bruker Tensor 27 spectrometer (Bruker, Karlsruhe, Germany). Nuclear magnetic resonance (NMR) spectra were on a Bruker AVIII-600 NMR instrument (¹H: 600 MHz, ¹³C: 150 MHz) equipped with CryoProbe (Bruker, Karlsruhe, Germany), with tetramethylsilane (TMS) as an internal standard. Chemical shift values (δ) are given in parts per million (ppm) and coupling constants in Hertz (Hz). The following abbreviations are used to designate multiplicities: s = singlet, d = doublet, t = triplet, m = multiplet, br = broad. Electrospray ionization (ESI) and high-resolution electrospray ionization (HRESIMS) were carried out an Agilent 1100 series LC/MSD ion trap mass spectrometer and an Agilent 6529B Q-TOF instrument (Agilent Technologies, Santa Clara, CA, USA), respectively. Preparative high performance liquid chromatography (Pre-HPLC) was performed on a Shimadzu LC-6A system (Shimadzu, Tokyo, Japan) equipped with a Shim-pack RP-C18 column (200 mm ×20 mm i.d., 10 μm, Shimadzu, Tokyo, Japan) and chiral preparative column (200 mm ×20 mm i.d., 10 μ m, Phenomenex Cellulose-2, USA) with flow rate at 10.0 ml/min and column temperature at 25 $^\circ$ C, detected by a binary channel UV detector at 210 and 240 nm.. All solvents used were of analytical grade (Jiangsu Hanbang Science and Technology. Co., Ltd.). Silica gel (200-300 mesh, Qingdao Haiyang Chemical Co., Ltd, Qingdao China) and RP-C18 silica (40-63 µm, FuJi, Japan) were used for column chromatography. Fractions obtained from column chromatography (CC) were monitored by thin-layer chromatography (TLC) with precoated silica gel GF254 (Qingdao Haiyang Chemical Co., Ltd, China) plates. Plant material

Air-dried the whole plants of *Hypericum elodeoides* were collected from Yunnan Province, China, in September 2017. A voucher specimen was deposited in the Department of Natural Medicinal Chemistry, China Pharmaceutical University (No. 2017-LHE) and authenticated by Professor Mian Zhang of the Research Department of Pharmacognosy, China Pharmaceutical University, China.

Extraction and isolation

The dried the whole plants of *H. elodeoides* (10.0 kg) was extracted three times (3 × 25L) with 95% aqueous EtOH under heating reflux, and the crude (583 g) was suspended in H₂O and extracted with petroleum ether (PE) (3 × 1L), methylene dichloride (MD) (3 × 1L), ethyl acetate (EA) (3 × 1L). The petroleum ether extract (206g) was subjected to a silica gel column, eluted with a gradient of PE-Me₂CO (1:0, 20:1, 10:1, 5:1, 1:1, v/v) to give ten fractions (A-J), which were combined based on HPLC and TLC. Fraction C (33.7 g) was chromatographed over a C18 silica gel column eluted with a gradient system of MeOH-H₂O (1:4, 5:5, 7:3, 8:2, 9:1, 1:0, v/v) to give twelve subfractions (Fr.C1 - Fr. C12). Fr. C1 (0.73 g) was separated with Pre-HPLC (MeOH-H₂O, 85:15, v/v) to **9** (t_R = 27.3 min, 6.8 mg). Fr. C2 (0.45 g) was separated with Pre-HPLC (MeOH-H₂O, 85:15, v/v) to obtain **7** (t_R = 25.1 min, 0.9 mg) and **8** (t_R = 26.5 min, 0.5 mg). Fr. C3 (0.68 g) was separated with Pre-HPLC (MeOH-H₂O, (5:5, 7:3, 8:2, 9:1, 1:0, v/v) to give ten subfractions (Fr.C1 - V) to obtain **1** (t_R = 40.2 min, 2.1 mg) and **2** (t_R = 59.7 min, 2.7 mg). Fraction E (17.9 g) was chromatographed over a C18 silica gel column eluted with a gradient system of MeOH-H₂O (5:5, 7:3, 8:2, 9:1, 1:0, v/v) to obtain compound **3** (t_R = 22.9 min, 1.5 mg). E4 (0.23 g) was separated with Pre-HPLC (MeOH-H₂O, 70:30, v/v) to obtain

compound **5** (t_R = 26.7 min, 2.4 mg) and **6** (t_R = 32.8 min, 2.3 mg). E5 (0.36 g) was separated with Pre-HPLC (MeOH–H2O, 75:25, v/v) to obtain compound **4** (t_R = 24.8 min, 1.8 mg).

Furtherly, compounds **1-2** and **5-6** were chirally separated *via* using a chiral preparative column eluting with MeOH-H₂O (v/v, 80:20).

Physical and chemical data

Elodeoidin A (**1**), yellowish gum; (+)-**1**: $[\alpha]_D^{25}$ = +39.2 (c 0.10, MeOH); ECD (MeOH) λ_{max} (Δ_{ε}) 219 (14.62), 244 (-1.55), 262 (0.74), 300 (-0.79), 342 (0.78), 379 (0.15); (-)-**1**: $[\alpha]_D^{25}$ = +40.7 (c 0.10, MeOH); ECD (MeOH) λ_{max} (Δ_{ε}) 219 (-14.84), 243 (1.93), 262 (-1.13), 299 (1.01), 346 (-0.71), 382 (-0.23); UV (MeOH) λ_{max} (log ε) = 227 (3.79); IR (KBr) ν_{max} 3473, 2971, 2931, 1716, 1463, 1383, 1288, 1151, 1050, 900 cm⁻¹; ¹H and ¹³C NMR (CDCl₃), see Table S1; HRESIMS m/z 429.2242 [M + Na]⁺ (calcd for C₂₃H₃₄O₆Na, 429.2248).

Elodeoidin B (**2**), yellowish gum; (+)-**2**: $[\alpha]_D^{25}$ = +81.7 (c 0.10, MeOH); ECD (MeOH) λ_{max} (Δ_{ε}) 219 (30.02), 243(-5.82), 264 (7.92), 302 (-2.50), 345 (3.13); (-)-**2**: $[\alpha]_D^{25}$ = +67.6 (c 0.10, MeOH); ECD (MeOH) λ_{max} (Δ_{ε}) 218 (-26.28), 242 (6.81), 264 (-4.79), 301 (1.16), 339 (-0.99), 378 (-0.28); UV (MeOH) λ_{max} (log ε) = 227 (4.11); IR (KBr) ν_{max} 3455, 2969, 2931, 2877, 1752, 1716, 1461, 1383, 1287, 1178, 1148, 1116, 963 cm⁻¹; ¹H and ¹³C NMR (CDCl₃), see Table S1; HRESIMS m/z 443.2396 [M + Na]⁺ (calcd for C₂₄H₃₆O₆Na, 443.2404).

Elodeoidin C (**3**), yellowish gum; $[\alpha]_D^{25}$ = -18.4 (c 0.10, MeOH); ECD (MeOH) λ_{max} (Δ_{ε}) 204 (5.6), 229 (-12.19), 266 (+5.58); UV (MeOH) λ_{max} (log ε) = 225 (4.08); IR (KBr) ν_{max} 3441, 2968, 2933, 2874, 1745, 1709, 1642, 1466, 1383, 1291, 1215, 1056, 954 cm⁻¹; ¹H and ¹³C NMR (CDCl₃), see Table S1; HRESIMS m/z 431.2034 [M + Na]⁺ (calcd for C₂₂H₃₂O₇Na, 431.2040).

Elodeoidin D (**4**): yellowish gum; $[\alpha]_D^{25} = -18.0$ (c 0.10, MeOH); ECD (MeOH) λ_{max} (Δ_{ε}) 229 (-1.05), 261 (+0.77), 333 (-0.15); UV (MeOH) λ_{max} (log ε) = 236 (4.09); IR (KBr) ν_{max} 3395, 2963, 2921, 2849, 1707, 1645, 1467, 1421, 1381, 1291, 1216, 953 cm⁻¹; ¹H and ¹³C NMR (MeOD), see Table S1; HRESIMS *m*/*z* 445.2193 [M + Na]⁺ (calcd for C₂₃H₃₄O₇Na, 445.2197).

Elodeoidin E (**5**), yellowish gum; (+)-**5**: $[\alpha]_D^{25}$ = +24.3 (c 0.10, MeOH); ECD (MeOH) λ_{max} (Δ_{ε}) 215 (+4.87), 237 (-11.74), 275 (+1.88), 300 (+0.88), 348 (+3.52); (-)-**5**: $[\alpha]_D^{25}$ = -48.1 (c 0.10, MeOH); ECD (MeOH) λ_{max} (Δ_{ε}) 219 (-8.99), 238 (+9.50), 277 (-0.76), 289 (-0.51), 357 (-4.14); UV (MeOH) λ_{max} (log ε) = 240 (4.15), 360 (3.92); IR (KBr) ν_{max} 3451, 2972, 2937, 2874, 1743, 1711, 1692, 1641, 1463, 1378, 1286, 1127, 1022, 979 cm⁻¹; ¹H and ¹³C NMR (CDCl₃), see Table S2; HRESIMS *m/z* 391.2114 [M + H]⁺ (calcd for C₂₂H₃₁O₆, 391.2115).

Elodeoidin F (**6**), yellowish gum; (+)-**6**: $[\alpha]_D^{25} = +13.1$ (c 0.10, MeOH); ECD (MeOH) λ_{max} (Δ_{ε}) 205 (0.67), 221 (5.61), 240 (-4.66), 349 (2.34); (-)-**6**: $[\alpha]_D^{25} = -26.7$ (c 0.10, MeOH); ECD (MeOH) λ_{max} (Δ_{ε}) 219 (-7.08), 239 (7.28), 347 (-1.60); UV (MeOH) λ_{max} (log ε) = 240 (4.18), 355 (4.01); IR (KBr) ν_{max} 3429, 2967, 2932, 2875, 1745, 1710, 1643, 1615, 1462, 1382, 1286, 1126, 1091, 1061 cm⁻¹; ¹H and ¹³C NMR (CDCl₃), see Table S2; HRESIMS *m/z* 405.2269 [M + H]⁺ (calcd for C₂₃H₃₃O₆, 405.2272).

Elodeoidin G (**7**), yellowish gum; (+)-**7**: $[\alpha]_D^{25}$ = +15.2 (c 0.10, MeOH); (-)-**7**: $[\alpha]_D^{25}$ = -13.5 (c 0.10, MeOH); UV (MeOH) $\lambda_{max}(\log \varepsilon)$ = 236 (3.95); IR (KBr) v_{max} 2926, 2850, 1639, 1465, 1383, 1119, 1015, 863, 690, 627 cm⁻¹; ¹H and ¹³C NMR (CDCl₃), see Table S3; HRESIMS *m/z* 387.1781 [M + Na]⁺ (calcd for C₂₀H₂₈O₆Na, 387.1778).

Elodeoidin H (8), yellowish gum; UV (MeOH) $\lambda_{max}(\log \varepsilon) = 234$ (3.90); IR (KBr) ν_{max} 2925, 2851, 1640, 1466, 1383, 1119, 1014, 862, 689, 628 cm⁻¹; ¹H and ¹³C NMR (CDCl₃), see Table S3; HRESIMS *m/z* 387.1778 [M + Na]⁺ (calcd for C₂₀H₂₈O₆Na, 387.1778).

Ethyl (E)-4-hydroxy-4,8-dimethylnona-2,7-dienoate (**9**), white powder; ¹H NMR (600 MHz, CDCl₃) $\delta_{\rm H}$ 6.96 (d, *J* = 15.6 Hz, 1H), 6.03 (d, *J* = 15.6 Hz, 1H), 5.18 – 5.05 (m, 1H), 4.21 (q, *J* = 7.1 Hz, 2H), 2.10 – 2.04 (m, 1H), 2.02 – 1.97 (m, 1H), 1.68 (s, 3H), 1.66 – 1.63 (m, 2H), 1.59 (s, 3H), 1.33 (s, 3H), 1.30 (t, J = 7.1 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃) $\delta_{\rm C}$ 166.9, 154.2, 132.8, 123.9, 118.9, 73.6, 60.6, 41.8, 28.1, 25.8, 22.9, 17.9, 14.4. HRESIMS m/z 227.1637 [M + H]⁺ (calcd for C₁₃H₂₃O₃, 227.1643).

Anti-inflammatory activity¹

The RAW264.7 cell line was purchased from the Chinese Academic of Sciences. The cells were cultured in DMEM containing 10% FBS with penicillin (100 U/mL) and streptomycin (100 U/mL) at 37 °C in a humidified atmosphere with 5% CO₂. The cells were allowed to grow in 96-well plates with 1 × 105 cells/well to treat test compounds. AfterS5 being incubated for 2 h, the cells were treated with 100 ng/mL of LPS for 18 h. Nitrite in culture media was measured to assess NO production using Griess reagent. The absorbance at 540 nm was measured on a microplate reader. N-monomethyl-L-arginine was used as the positive control. Cytotoxicity was determined by the MTT method, after 48 h incubation with test compounds. All the experiments were performed in three independent replicates.

Cells were initially treated with LPS (1 μ g/mL) for a certain time. The total proteins were extracted as previously described.¹ Total proteins were electrophoresed on SDS-PAGE and transferred onto a PVDF membrane (Bio-Rad Laboratories, Hercules, CA, USA). The membranes were washed with TBST buffer, treated with 5% skimmed milk for 2 h at 25 °C, and then treated with primary antibodies for 12 h at 4 °C. After being washed with TBST, the membranes were probed with secondary antibody at room temperature. Lastly, the protein blots were read on a ChemiDOC XRS + system (Bio-Rad Laboratories). **Table S4** The anti-inflammatory and antibacterial activity of the tested compounds

Compound	IC ₅₀ (μM)			
(+)-1	33.36 ± 4.30			
(+)-5	9.05 ± 0.97			
(-)-5	6.06 ± 0.41			
(+)-6	9.73 ± 0.47			
(-)-6	10.46 ± 0.14			
NMLA	39.38 ± 0.90			

NMLA was n-monomethyl-l-arginine, each value represents as the mean ± sd from three independent experiments.

References:

(1) Wei S.S; Chi J.; Zhou M.M.; Li R.J.; Li Y.R.; Luo J.; Kong L.Y. Ind. Crop. Prod. 2019, 137: 367-376.

CALCULATION SECTION

Calculation quantum-chemical ¹³C NMR for 5

In general, conformational analyses were carried out *via* random searching in the Sybyl-X 2.0 using the MMFF94 force field with an energy cutoff of 3.0 kcal/mol.¹ The results showed one lowest energy conformer for **5**. Subsequently, All conformers for **5** was re-optimized using DFT at the b3lyp/6-311+g(2d, p) level by the GAUSSIAN 09 program.² The 13C shielding constants were calculated using the Gauge-Independent Atomic Orbital (GIAO) method at the b3lyp/6-31g(d) level with SMD in CDCl₃.³ To get the final ¹³CNMR chemical shifts, the ¹³C NMR chemical shifts of the conformers were averaged according to the Boltzmann distribution theory and their relative Gibbs free energy (ΔG).

No.	$\delta_{calcd.}$	$\delta_{ ext{exp.}}$	$\delta_{ ext{corr.}}$	Δ_{δ}	No.	$\delta_{ ext{calcd.}}$	$\delta_{ ext{exp.}}$	$\delta_{ ext{corr.}}$	Δ_{δ}
1	141.3	145.3	146.6	-1.3	1'	107.1	112.6	108.0	4.6
2	129.8	142.8	138.0	4.8	2'	45.4	48.2	49.7	-1.4
3	156.6	148.4	160.1	-11.7	3'	69.6	77.8	74.2	3.6
4	196.9	204.7	202.8	1.9	4'	35.2	40.6	39.4	1.3
5	44.1	48.0	48.3	-0.4	5'	20.7	23.4	24.7	-1.3
6	195.6	203.6	201.5	2.1	6'	42.3	47.1	46.5	0.6
7	197.2	205.1	203.1	2.0	7'	78.6	81.3	83.2	-1.9
8	36.3	41.9	40.5	1.4	8'	16.8	20.2	20.8	-0.5
9	12.1	17.3	16.0	1.2	9'	23.6	28.2	27.6	0.6
10	13.3	17.3	17.2	0.0	10'	22.9	27.2	26.9	0.3
11	15.6	19.9	19.5	0.4					
12	19.8	20.6	23.8	-3.2					
<i>∆</i> _δ = δ	$_{ m exp.}$ - $\delta_{ m corr.}$								

Table S5 Experimental and calculated ¹³C NMR data for 5

References:

(1) Sybyl Software, version X 2.0; Tripos Associates Inc.: St. Louis, MO, 2013.

- (2) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, Jr., J. A.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, Ö.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J., Gaussian 09, Rev. C 01; Gaussian, Inc., Wallingford CT, 2009.
- (3) K. Wolinski, J. F. Hilton, and P. Pulay, Efficient Implementation of the Gauge-Independent Atomic Orbital Method for NMR Chemical Shift Calculations, J. Am. Chem. Soc., 1990, 112, 8251-60.

Calculation ECD for 1-6

Monte Carlo conformational searches were carried out by means of the Spartan's 10 software using Merck Molecular Force Field (MMFF). The conformers with Boltzmann-population of over 5% were chosen for ECD calculations, and then the conformers were initially optimized at B3LYP/6-31g (d, p) level in MeOH using the CPCM polarizable conductor calculation model. The theoretical calculation of ECD was conducted in MeOH using Time-dependent Density functional theory (TD-DFT) at the B3LYP/6-31+g (d, p) level for all conformers of compounds **1-6**. Rotatory strengths for a total of 30 excited states were calculated. ECD spectra were generated using the program SpecDis 1.6 (University of Würzburg, Würzburg, Germany) and GraphPad Prism 8 (University of California San Diego, USA) from dipole-length rotational strengths by applying Gaussian band shapes with sigma = 0.3 eV. The calculated conformation as follows:



Table S6 The coordinate for lowest-energy conformer (-)-1 and 3 in ECD calculation

Atom		(-)- 1		Atom		3	
	Х	Y	Z	7.0011	Х	Y	Z
С	-5.228727	0.22243	0.120562	С	3.982721	-0.5364	-2.37594
С	-4.046798	-0.156185	-0.78928	С	4.464489	0.02246	-1.02673
С	-3.000598	0.961352	-0.832612	С	5.417224	1.206836	-1.25977
С	-1.680664	0.415362	-0.364656	С	3.276473	0.435596	-0.12591
С	-0.432956	1.277165	-0.37562	С	3.678455	0.979507	1.264869
С	0.4251	0.316248	-2.439197	С	2.393775	0.851621	2.093713
С	-0.588075	2.685409	0.205594	С	1.779705	-0.49682	1.649909
С	0.868805	3.030194	0.54462	С	2.083955	-1.63619	2.615538
С	1.475741	1.664321	0.982538	С	2.298021	-0.72812	0.194463
С	1.469997	1.49285	2.501865	С	1.023468	-0.81087	-0.67127
С	2.863167	1.43706	0.359017	С	-0.05622	-0.15463	0.229427
С	3.48327	0.052538	0.639847	С	-1.46909	-0.59765	0.001418
С	4.743911	-0.174016	-0.151496	С	-2.21114	-1.87278	0.093975
С	5.000787	-1.134022	-1.053958	С	-3.68153	-1.558	-0.24173
С	4.038617	-2.225214	-1.458959	С	-4.59912	-1.87712	0.952475
С	6.338967	-1.193686	-1.753348	С	-4.12412	-2.32973	-1.49934
С	-1.819925	-0.889129	-0.024996	С	-3.66468	-0.03321	-0.52102
С	-0.770015	-1.891794	0.400773	С	-2.25658	0.422859	-0.35933
С	-0.943006	-2.548192	1.764332	С	-1.434	1.689046	-0.49851
С	0.208891	-3.510558	2.064755	С	-1.87441	2.921271	0.322616
С	-1.153448	-1.514497	2.887012	С	-3.08918	3.630787	-0.29448
С	-4.535031	-0.494893	-2.212188	С	-2.11562	2.564248	1.796577
С	-3.248333	-1.319668	-0.203315	н	2.724898	1.22437	-0.65637
н	1.3819	3.372378	-0.363102	н	2.829375	-1.68016	0.121812
н	-5.741623	1.098561	-0.2875	н	1.106839	-0.25228	-1.60529
н	-5.932378	-0.613148	0.181558	Н	3.419478	0.214383	-2.94259
н	-4.896373	0.464333	1.136421	н	4.842753	-0.83162	-2.99198
н	-0.391299	-0.397285	-2.603626	н	3.348108	-1.41685	-2.23971
н	0.776962	0.690547	-3.40323	н	5.843391	1.557603	-0.31575
н	1.235518	-0.200747	-1.919404	Н	6.246337	0.906383	-1.91345
н	-1.065781	3.364039	-0.500812	н	4.902757	2.045585	-1.74354
н	-1.177354	2.653304	1.128314	Н	5.868843	-1.34075	-0.87459
н	0.755924	4.850225	1.224169	н	4.050423	2.009048	1.229512
Н	1.742079	0.466874	2.765019	Н	4.476115	0.353729	1.681268

н	2.183238	2.177918	2.968248	н	1.694833	1.651619	1.831004
н	0.480425	1.706638	2.915375	н	2.56637	0.897976	3.17479
н	2.768793	1.570296	-0.725268	н	1.712462	-2.58955	2.224667
н	3.533456	2.231544	0.716897	Н	3.164825	-1.72546	2.769976
н	3.720397	-0.025845	1.710914	Н	1.608812	-1.45234	3.585332
н	2.734779	-0.71615	0.427338	Н	0.281852	-2.60159	-0.28392
н	5.536739	0.551721	0.044158	н	-5.62609	-1.58085	0.718047
н	3.870458	-2.205376	-2.545056	Н	-4.57405	-2.95062	1.163766
н	4.461976	-3.214498	-1.233832	Н	-4.28611	-1.34328	1.856856
н	3.064219	-2.16155	-0.969581	н	-3.47823	-2.10938	-2.35633
н	7.007282	-0.389347	-1.429525	Н	-4.08133	-3.40621	-1.3071
н	6.843452	-2.151844	-1.563233	Н	-5.14965	-2.05165	-1.76118
н	6.219962	-1.118836	-2.843736	Н	-0.80316	2.752898	-1.98386
н	-1.879283	-3.119822	1.662914	Н	-1.00754	3.599566	0.279352
н	1.155765	-2.968782	2.166559	Н	-3.95455	2.962245	-0.34269
н	0.018507	-4.045399	3.00153	н	-3.35873	4.502611	0.312423
н	0.332911	-4.243832	1.263585	н	-2.88411	3.975499	-1.31219
н	-2.004835	-0.855608	2.685482	Н	-3.03263	1.973196	1.912513
н	-1.349865	-2.029257	3.833269	н	-1.28136	1.991796	2.211944
н	-0.265293	-0.888482	3.015772	н	-2.23949	3.476296	2.390273
н	-3.704499	-0.773991	-2.870078	0	5.157778	-1.01152	-0.30264
н	-5.237414	-1.333228	-2.172465	0	0.671154	-2.13392	-1.04586
н	-5.037001	0.375675	-2.645438	0	-4.64229	0.636739	-0.7869
0	-0.01097	1.47133	-1.721075	0	-1.75275	-2.96826	0.366295
0	1.021415	3.989818	1.582476	0	-1.35581	1.959914	-1.87977
0	0.554728	0.666459	0.429412	0	-0.13728	1.27403	-0.00712
0	0.098612	-2.208595	-0.391112	0	0.325806	-0.4218	1.546141
0	-3.215638	2.105858	-1.181037				
0	-3.693124	-2.417305	0.076413				

 Table S7 The coordinate for lowest-energy conformer (+)-5 in ECD calculation

-								
	Atom	Х	Y	Z	Atom	х	Y	Z
	С	2.292602	1.349431	-0.24391	н	3.173465	3.86267	-1.06889
	С	1.089698	0.493451	-0.09384	н	-1.95437	2.015009	0.614612
	С	-0.02333	1.32611	0.371883	н	-3.89712	-0.8293	-2.49362
	С	0.549256	2.629183	0.83795	н	-5.33174	-0.37881	-1.56323
	С	2.01278	2.727455	0.370842	н	-4.03496	-2.60067	-0.76829
	С	2.960516	2.990639	1.555413	н	-4.41725	-1.39384	0.467281
	С	2.147309	3.836128	-0.69235	н	-1.89067	-1.24223	3.269042
	С	-1.35867	1.200704	0.208253	н	-2.52431	0.039839	2.211247
	С	-2.10147	0.204523	-0.64475	н	-3.47464	-1.42534	2.505977
	С	-4.24883	-0.53393	-1.49699	н	-1.32498	-3.77489	0.530579
	С	1.212394	-0.85344	-0.24316	н	-1.46097	-3.56931	2.287263
	С	-2.3349	-1.30525	-0.2122	н	-2.92209	-3.61522	1.283114
	С	-3.84408	-1.57304	-0.44637	н	3.725618	-1.20448	0.666062
	С	-3.51243	0.736382	-1.03872	н	4.709396	-2.75928	-1.79373
	С	-1.80895	-1.74764	1.165586	н	5.081777	-1.07133	-1.40707
	С	-2.4633	-1.03858	2.359955	н	5.698407	-2.37526	-0.36893
	С	-1.8845	-3.27231	1.323852	н	3.095154	-4.09037	-0.18137
	С	2.391704	-1.53438	-0.95714	н	2.36505	-3.24806	1.196723
	С	3.58597	-1.96181	-0.11348	н	4.098429	-3.61514	1.199799
	С	4.848627	-2.04739	-0.97576	н	-3.01567	1.521323	-3.00983
	С	3.257916	-3.30986	0.568924	н	-4.49797	2.189921	-2.31628
	С	-3.48054	1.85654	-2.07736	н	-2.92203	2.719003	-1.70225
	н	-1.52368	0.136707	-1.57659	н	-4.97052	1.58576	-0.03572
	н	-1.78651	-1.91447	-0.93636	0	-0.0441	3.510204	1.432402
	н	3.995234	3.026381	1.204181	0	3.368079	1.010841	-0.7194
	н	2.701755	3.943446	2.0247	0	-0.4275	-1.32454	1.319732
	н	2.883247	2.205868	2.314865	0	2.26115	-1.79678	-2.13457
	н	1.47691	3.665463	-1.54087	0	0.364045	-1.8165	0.179009
_	Н	1.897017	4.803277	-0.24793	0	-4.1065	1.211233	0.182291



NMR, HRESIMS, UV, and IR spectrum of 1 (Figure S7-S15)

Figure S7 ¹H NMR (600 MHz) spectrum of 1 in CDCl₃ (the above) and DMSO- d_6 (the following figure).



Figure S8 13 C NMR (150 MHz) spectrum of 1 in CDCl₃ (the above figure) and DMSO- d_6 (the following figure).



Figure S9 HSQC spectrum of 1 in CDCl₃ (the above figure) and DMSO- d_6 (the following figure).



Figure S10 HMBC spectrum of 1 in CDCl₃ (the above figure) and DMSO- d_6 (the following figure).



Figure S11 ROESY spectrum of 1 in CDCl₃ (the above figure) and DMSO- d_6 (the following figure).



Figure S12 ¹H-¹H COSY spectrum of 1 in CDCl₃.



Elemental Composition Calculator

Target m/z:	429.2242	Result type: Positive ions		Species:	[M+Na] ⁺			
Elemo	ents:	C (0-80); H (0-120); O (0-30)						
Ion Formula		Ca	lcalated m/z	PPM Error				
C23H34O6Na			429.2248	0.7				

Agilent Technologies

Figure S13 HRESIMS spectrum of 1.



Figure S14 IR spectrum of 1.



Figure S15 UV spectrum of 1.



NMR, HRESIMS, UV, and IR spectrum of 2 (Figure S16-S23)

Figure S16 ¹H NMR (600 MHz) spectrum of 2 in CDCl₃.



Figure S17 ¹³C NMR (150 MHz) spectrum of 2 in CDCl₃.



Figure S18 HSQC spectrum of 2 in CDCl₃.



Figure S19 HMBC spectrum of 2 in CDCl₃.



Figure S20 ROESY spectrum of 2 in CDCl₃.



Elemental Composition Calculator

392 394 396 398 400 402 404 406 408 410 412 414 416 418 420 422 424 426 428 430 432 434 436 438 440 442 444 446 448 450 452 454 456 458 460 462 464 466 468 47/ Counts vs. Mass-to-Charge (m/z)

Target m/z:	443.2396	Result type:	Positive ions	Species:	[M+Na] ⁺		
Elemo	ents:	C (0-80); H (0-120); O (0-30)					
Ion Formula		Ca	lcalated m/z	PPM Error			
C24H36O6Na			443.2404	0.8			

Agilent Technologies

Figure S21 HRESIMS spectrum of 2.



Figure S22 IR spectrum of 2.



Figure S23 UV spectrum of 2.



NMR, HRESIMS, UV, and IR spectrum of 3 (Figure S24-S32)

Figure S24 ¹H NMR (600 MHz) spectrum of 3 in CDCl₃ (the above figure) and DMSO- d_6 (the following figure).



Figure S25 ¹³C NMR (150 MHz) spectrum of 3 in CDCl₃ (the above figure) and DMSO- d_6 (the following figure).



Figure S26 HSQC spectrum of 3 in CDCl₃ (the above figure) and DMSO- d_6 (the following figure).



Figure S27 HMBC spectrum of 3 in CDCl₃ (the above figure) and DMSO- d_6 (the following figure).



Figure S28 ROESY spectrum of 3 in CDCl₃ (the above figure) and DMSO- d_6 (the following figure).



Figure S29 ¹H-¹H COSY spectrum of 3 in CDCl₃.



Elemental Composition Calculator

432,2076 447.1841 413 415 416 417 418 419 420 421 422 423 424 425 426 427 428 430 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 Counts vs. Mass-to-Charge (m/z)

Target m/z:	431.2034	Result type:	Positive ions	Species:	[M+Na] ⁺		
Elem	ents:	C (0-80); H (0-120); O (0-30)					
Ion Formula		Ca	lcalated m/z	PPM Error			
C22H32O7Na			431.2040	0.70			

Agilent Technologies

Figure S30 HRESIMS spectrum of 3.









NMR, HRESIMS, UV, and IR spectrum of 4 (Figure S33-S40)



Figure S33 ¹H NMR (600 MHz) spectrum of 4 in MeOD.



Figure S34 ¹³C NMR (150 MHz) spectrum of 4 in MeOD.



Figure S35 HSQC spectrum of 4 in MeOD.



Figure S36 HMBC spectrum of 4 in MeOD.



Figure S37 ROESY spectrum of 4 in MeOD.



Elemental Composition Calculator

Target m/z:	445.2193	Result type: Positive ions		Species:	[M+Na] ⁺
Elements:		С (0-80); Н (0-120); О (0-30)			
Ion Formula		Calcalated m/z		PPM Error	
C23H34O7Na		445.2197		0.76	

Agilent Technologies

Figure S38 HRESIMS spectrum of 4.



Figure S39 IR spectrum of 4.



Figure S40 UV spectrum of 4.



NMR, HRESIMS, UV, and IR spectrum of 5 (Figure S41-S49)

Figure S41 ¹H NMR (600 MHz) spectrum of 5 in CDCl₃ (the above figure) and DMSO- d_6 (the following figure).



Figure S42 ¹³C NMR (150 MHz) spectrum of 5 in CDCl₃ (the above figure) and DMSO- d_6 (the following figure).



Figure S43 HSQC spectrum of 5 in CDCl₃ (the above figure) and DMSO- d_6 (the following figure).



Figure S44 HMBC spectrum of 5 in CDCl₃ (the above figure) and DMSO- d_6 (the following figure).



Figure S45 ROESY spectrum of 5 in CDCl₃ (the above figure) and DMSO- d_6 (the following figure).



Figure S46 ¹H-¹H COSY spectrum of 5 in CDCl₃.



Elemental Composition Calculator

Target m/z:	391.2114	Result type: Positive ions		Species:	$[M+H]^+$
Elements:		C (0-80); H (0-120); O (0-30)			
Ion Formula		Calcalated m/z		PPM Error	
C22H31O6		391.2115		0.17	

Agilent Technologies

Figure S47 HRESIMS spectrum of 5.



Figure S48 IR spectrum of 5.



Figure S49 UV spectrum of 5.



110 100 fl (ppm)

90 80

70

60 50

20 10

30

NMR, HRESIMS, UV, and IR spectrum of 6 (Figure S50-S57)

Figure S51 ^{13}C NMR (150 MHz) spectrum of 6 in CDCl3.

170 160 150 140 130 120

210

200 190 180



Figure S52 HSQC spectrum of 6 in CDCl₃.



Figure S53 HMBC spectrum of 6 in CDCl₃.



Figure S54 ROESY spectrum of 6 in CDCl₃.



Elemental Composition Calculator

Target m/z:	405.2269	Result type: Positive ions		Species:	$[M+H]^+$
Elements:		С (0-80); Н (0-120); О (0-30)			
Ion Formula		Calcalated m/z		PPM Error	
C23H33O6		405.2272		0.66	

Agilent Technologies

Figure S55 HRESIMS spectrum of 6.



Figure S56 IR spectrum of 6.



Figure S57 UV spectrum of 6.

NMR, HRESIMS, UV, and IR spectrum of 7 (Figure S58-S66)



Figure S59 ¹³C NMR (150 MHz) spectrum of 7 in CDCl₃.



Figure S60 HSQC spectrum of 7 in CDCl₃.



Figure S61 HMBC spectrum of 7 in $CDCl_3$.



Figure S62 ¹H-¹H COSY spectrum of 7 in CDCl₃.



Figure S63 ROESY spectrum of 7 in CDCl₃.



Elemental	Composition	Calculator
-----------	-------------	------------

Target m/z: 387.178	Result type: Positive ions		Species:	[M+Na] ⁺		
Elements:		C (0-80); H (0-120); O (0-30)				
Ion Formula	Ca	Calcalated m/z		PPM Error		
C20H28O6Na		387.1778		-0.73		

Agilent Technologies

Figure S64 HRESIMS spectrum of 7.



Figure S65 IR spectrum of 7.



Figure S66 UV spectrum of 7.

NMR, HRESIMS, UV, and IR spectrum of 8 (Figure S67-S75)



Figure S68 ¹³C NMR (150 MHz) spectrum of 8 in CDCl₃.



Figure S69 HSQC spectrum of 8 in CDCl₃.



Figure S70 HMBC spectrum of 8 in CDCl₃.



Figure S71 ¹H-¹H COSY spectrum of 8 in CDCl₃.



Figure S72 ROESY spectrum of 8 in CDCl₃.



Elemental Composition Calculator

Elements: C (0-80); H (0-120); O (0-30) Ion Formula Calcalated m/z PPM Error	Target m/z:	387.1778	Result type: Positive ions		Species:	[M+Na] ⁺
Ion Formula Calcalated m/z PPM Error	Elements:		С (0-80); Н (0-120); О (0-30)			
	Ion Formula		Calcalated m/z		PPM Error	
C20H28O6Na 387.1778 -0.1	C20H28O6Na		387.1778		-0.1	

Agilent Technologies

Figure S73 HRESIMS spectrum of 8.



Figure S74 IR spectrum of 8.



Figure S75 UV spectrum of 8.



NMR and HRESIMS spectrum of 9 (Figure S76-S78)

Figure S77 ¹³C NMR (150 MHz) spectrum of 9 in CDCl₃.



Elemental Composition Calculator

Target m/z:	227.1637	Result type: Positive ions		Species:	$[M+H]^+$
Elements:		С (0-80); Н (0-120); О (0-30)			
Ion Formula		Calcalated m/z		PPM Error	
C13H23O3		227.1643		0.6	

Figure S78 HRESIMS spectrum of 9.

¹H NMR spectrum of MTPA Esters of (+)-1 (Figure S79-S80)



Figure S79 ¹H NMR (600 MHz) spectrum of *R*-MTPA Esters of (+)-1 in CDCl₃.



Figure S80 ¹H NMR (600 MHz) spectrum of S-MTPA Esters of (+)-1 in CDCl₃.